Envision Healthcare (EVHC) Reports Q2 Adj. EPS of $0.85, Beats on Revenues; FY17 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Envision Healthcare (EVHC) PT Lowered to $57 at Mizuho Securities
August 9, 2017 1:17 PM EDTMizuho Securities lowered its price target on Envision Healthcare (NYSE: EVHC) to $57.00 (from $65.00) while maintaining a Neutral rating. Analyst Ann Hynes lowered the price target given the guidance reduction and headwinds in the physician services industry.
Mizuho believes that the... More
Envision Healthcare (EVHC) PT Lowered to $57 at Mizuho Securities on 2Q Report; 'Guidance Reduction & Headwinds in Physician Services Industry'
August 9, 2017 12:31 PM EDTMizuho Securities lowered its price target on Envision Healthcare (NYSE: EVHC) to $57.00 (from $65.00) while maintaining a Neutral rating, following the company's second quarter earnings report.
Analyst Ann Hynes notes the company delivered second quarter earnings per share results in above the Street's estimates on $1.95... More



